{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Bio-Path Holdings, Inc."},"Symbol":{"label":"Symbol","value":"BPTH"},"Address":{"label":"Address","value":"4710 BELLAIRE BOULEVARD,SUITE 210, BELLAIRE, Texas, 77401, United States"},"Phone":{"label":"Phone","value":"+1 832 742-1357"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003."},"CompanyUrl":{"label":"Company Url","value":"https://www.biopathholdings.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Ana Tari Ashizawa","title":"Senior VP-Research, Development & Clinical Design"},{"name":"Michael Roberts","title":"Director-Manufacturing Planning & Engineering"},{"name":"Peter H. Nielsen","title":"Chairman, President, CEO, CFO & Treasurer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}